EGFR and non-small cell lung carcinoma: In recent years, the prognosis and quality of life of patients with advanced NSCLC harboring EGFR mutations has changed dramatically due to the incorporation of tyrosine kinase inhibitors (TKIs), now standard of care as first-line therapy [2].